InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
Stock Information for InflaRx N.V.
Loading
Please wait while we load your information from QuoteMedia.